Control Versus Cure? How to Determine the Value of Oncology Treatments within Managed Care: A Focus on Multiple Myeloma

Module I: An Introduction to Multiple Myeloma: Diagnosis and Risk Stratification
     0.5 CME credits

Module II: Myeloma Management Treatment Selection and Duration of Therapy
     0.25 CME credits

Module III: Managed Care Strategies for the Management of Multiple Myeloma
     1.0 CME credits

• Part 1: Applying CER as a Decision-Support Tool for Anti-Myeloma Agents to Reduce Treatment Variability
• Part 2: Collaborating to Improve Care of Multiple Myeloma Patients: Pharmacy Benefit Designs and Specialty Pharmacy Cancer Care Services

• Release date: September 30, 2014
• Expiration date: April 30, 2016
• Estimated Time to Complete Activity:
  • Module I: 0.5 hours
  • Module II: 0.25 hours
  • Module III: 1.0 hours
• Compatible with (IE 6 and up, Firefox, Safari)

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with multiple myeloma including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

Leaders from managed care organizations (MCOs) and other payers have identified the management of multiple myeloma (MM) as a priority area for optimizing clinically- and economically-appropriate care for their members.  In light of new drug developments as well as expanding uses of current agents, payers need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes. The enduring modules will include a unique point/counter-point design to debate the value proposition of MM drug sequences, treatment combinations, and duration of therapy.  The faculty panel includes an academic hematologist, a community-based hematologist, and managed care experts.

MODULE I EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Discuss the nature and validity of current debates among members of the hematology community regarding therapeutic decision-making for MM patients, including the clinical data that support various perspectives
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

MODULE II EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Discuss the nature and validity of current debates among members of the hematology community regarding therapeutic decision-making for MM patients, including the clinical data that support various perspectives
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

MODULE III EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Demonstrate the value of comparative effectiveness research (CER) as a decision-support tool to appropriately invest resources and reduce treatment variability among MM patients
• Implement innovative oncology pharmacy benefit design models and specialty pharmacy management services
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

MODULE I - DISTINGUISHED FACULTY

Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC Click here for biography

Joseph Mikhael, MD, MEd, FRCPC, FACP Associate Dean, Mayo School of Graduate Medical Education Deputy Director—Education Mayo Clinic Cancer Center Associate Professor, Mayo College of Medicine Mayo Clinic in Arizona Click here for biography

Rafat Abonour, MD Professor of Medicine Director, Multiple Myeloma Program Medical Director, Clinical Research Office Indiana University Simon Cancer Center Click here for biography

MODULE II - DISTINGUISHED FACULTY

Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC Click here for biography

Joseph Mikhael, MD, MEd, FRCPC, FACP Associate Dean, Mayo School of Graduate Medical Education Deputy Director—Education Mayo Clinic Cancer Center Associate Professor, Mayo College of Medicine Mayo Clinic in Arizona Click here for biography

Rafat Abonour, MD Professor of Medicine Director, Multiple Myeloma Program Medical Director, Clinical Research Office Indiana University Simon Cancer Center Click here for biography

MODULE III - DISTINGUISHED FACULTY

Diana Brixner, PhD, RPh Professor and Chair, Department of Pharmacology Executive Director Outcomes Research Center, College of Pharmacy Director of Outcomes, Personalized Health Care Program University of Utah Click here for biography

Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC Click here for biography

ACCREDITATION

Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC.  The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation (all modules)
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Module I: 0.5 CME credits
• Module II: 0.25 CME credits
• Module III: 1.0 CME credit

Pharmacist Continuing Education
Accreditation Statement

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation (all modules)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

• Module I: UAN: 0809-9999-14-093-H01-P, 0.5 contact hours (knowledge)
• Module II: UAN: 0809-9999-14-200-H01-P, 0.25 contact hours (knowledge)
• Module III: UAN: 0809-9999-14-199-H01-P, 1.0 contact hours (application)

Nursing Continuing Education
Credit Designation (all modules)
This educational activity for up to 1.8 contact hours is provided by Postgraduate Institute for Medicine

• Module I: 0.5 contact hours
• Module II: 0.3 contact hours
• Module III: 1.0 contact hours

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period September 1, 2014 through March 31, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitoring Service.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.